Dr. Reddy's Laboratories heads into its September 17 quarterly earnings with short sellers adding pressure at a steady pace and options traders tilting decisively toward calls.
Short interest has climbed roughly 15% over the past month, reaching approximately 24.6 million shares as of September 10. That move accelerated sharply in the final two sessions of last week — a 7% single-day jump on September 10 alone brought the one-week gain to just over 10%. The stock itself has drifted about 4% lower over the past month, closing at $11.90, though it clawed back 1.6% on the final session before the weekend. The borrow market does not look squeezed: cost to borrow is a low 0.83%, down more than 57% from a month ago, and availability has loosened materially — jumping roughly 73% week-on-week to 82% — meaning there is still meaningful room in the lending pool for new shorts to enter. The ORTEX short score, at 63.6, has been remarkably stable over the past two weeks, suggesting this is a slow-building rather than panicked bear positioning.
Options traders are telling a different story. The put/call ratio has dropped to 0.31, well below its 20-day average of 0.34, pointing to heavier call volume relative to puts — a more bullish lean than has been typical recently. The PCR z-score of -0.66 is not extreme, but the direction is clear: options buyers are not rushing for downside protection into this print. The 52-week range on the PCR runs from 0.009 to 1.60, which places the current reading toward the bullish end of the historical band. That divergence from the rising short interest is the central tension in the setup.
The ownership picture adds one layer worth noting. K. Satish Reddy filed a Schedule 13D/A last September disclosing a 13.58% stake — classified as an activist filing under SEC rules, though for a founding-family member this more likely reflects governance structure than an outside challenge. The filing is now over a year old, and stakes are as-last-disclosed; positions can change without a further filing once below the 5% threshold. BlackRock holds around 4% on a passive 13G basis and added marginally in recent months. Analyst data in the snapshot is largely stale — the most recent credible target-price moves date to mid-2025 or earlier, and the mean consensus target of roughly $1,280 appears to reference the Indian-listed shares rather than the US ADR at $11.90, so that figure should not be read alongside the ADR price directly.
The print will test whether Dr. Reddy's can demonstrate that margin pressures in US generics are stabilising — and whether the accelerating short interest of the past two weeks reflects genuine conviction about a weak quarter, or simply pre-earnings hedging that unwinds quickly once the numbers land.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
